The Clinical Utility of Fecal Caprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy

Crohn's Disease Clinical Trial

Official title:

The Clinical Utility of Fecal Calprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy: A Prospective Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01266629
• Other study ID #: 2010-147
• Status: Recruiting
• Phase: N/A
• First received: December 23, 2010
• Last updated: January 10, 2011
• Start date: December 2010
• Est. completion date: September 2011

Study information

• Verified date: October 2010
• Source: Shaare Zedek Medical Center
• Contact: Ariella Shitrit, MD
• Phone: 972-525751515
• Email: davariel[@]zahav.net.il
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Observational

Clinical Trial Summary

Capsule endoscopy (CE) is considered as a gold standard examination for small bowel Crohn's disease. However, it is time-consuming, expensive and results are largely influenced by the operator's skills. We, therefore, want to assess the predictive value of fecal calprotectin and lactoferrin in patients undergoing CE.

Description:

Capsule endoscopy (CE), a novel and wireless method of investigating the small bowel uses a remote instrument that is swallowed and propelled through the gastrointestinal tract by the action of peristalsis. The capsule contains an imaging device, which transmits images of the intestine to sensors on the abdominal wall. It has the ability to detect diffuse mucosal disease but without the inadvertent radiation exposure. Numerous studies have compared the utility of small bowel radiology to CE for the investigation of Crohn's disease. A recent meta-analysis showed that CE is superior to small bowel radiology, CT enterography and ileo-colonoscopy in the setting of suspected Crohn's disease. Capsule endoscopy has now developed an established role in the investigation pathway of small bowel Crohn's disease. However CE requires placement of an eight-lead sensor array over the abdomen that receives image and localization data transmitted from the capsule. The current process of applying this array to the skin has several disadvantages: firstly, it is time-consuming; secondly, it can be cumbersome for the patient; and thirdly, it is often difficult to place the leads consistently. Moreover, CE is expensive and results are largely influenced by the operator's skills.

Among the available fecal biomarkers for the diagnosis and monitoring of inflammatory bowel disease (IBD), only calprotectin and lactoferrin have translated into useful clinical tools.

Calprotectin (MRP8/14) is a calcium-binding heterodimer of the S100 protein family, presents in granulocytes, macrophages, and epithelial cells of humans and other mammals.It is believed to play an essential role in immunity. Calprotectin is released upon neutrophil/monocyte activation, when it can be detected in serum and body fluids, including stool. It is poorly degraded during passage through the gastrointestinal tract and remains stable in refrigerated storage. Together, these features make calprotectin a potentially useful marker of clinical inflammatory and neoplastic states. Recently, several studies suggested that a high fecal calprotectin concentration may distinguish patients with inflammatory bowel disease (IBD) from patients with irritable bowel syndrome (IBS).

Lactoferrin (LF) is an iron binding glycoprotein secreted by most mucosal membranes and a major component of secondary granules of polymorphonuclear neutrophils, a component of the inflammatory response. A number of studies have investigated the use of lactoferrin as a non invasive marker in the distinction of inflammatory bowel disease (IBD) and non inflammatory conditions. Whilst a high sensitivity of LF has been reported for active IBD in comparison to IBS, the distinction of inactive IBD and IBS is less clear . Lactoferrin can be detected using simple and cheap techniques and it has excellent stability in feces over a long period of time. Fecal lactoferrin has a good diagnostic precision for separating organic and functional intestinal disease.

The aim of this prospective study is to assess the clinical utility of fecal calprotectin and lctoferrin in patients undergoing CE.

Exclusion criteria Intake of nonsteroidal agents and/or antibiotics during the three months preceding the study, concomitant serious illness, pregnancy, alcohol abuse, and evidence of a respiratory tract infection.

Study protocol After obtaining informed consent from the patients, data will collect on patient symptoms including the presence of abdominal pain, weight loss, diarrhoea, abdominal mass, extra-intestinal manifestations or family history of IBD. All patients will undergo a non diagnostic colonoscopy and gastro copy prior to CE referral.

Study protocol include diagnostic CE and stool examinations. Stool Analysis Prior to CE preparation, patients will ask to supply a stool specimen which they were to store in a household freezer and bring with them on the day of examination. The specimens will freeze at -20°C until assay. Fecal calprotectin levels will determine with a commercially available quantitative enzyme-linked immunoassay (Calpreset; Eurospital, Trieste, Italy and IBD SCAN) . Faecal lactoferrin test will perform on each thawed sample as previously described .Normal levels of calprotectin will define as 25 mg/kg stool.

Capsule endoscopy The description of CE is well reported in the literature (Pillcam SB, Given Imaging, Yoqneum,Ltd) .Patients will fast overnight for 12 hours after ingestion of two sachets of polyethylene glycol solution (Kleen-Prep, Norgine). Patients were allowed to drink 2 hours after and eat a light snack 4 hours after ingestion of the capsule.

Blood markers In addition, blood will collect from all patients for measurement of complete blood count, C-reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR) by standard methods (normal values ESR <12 mm/h; CRP <5 mg/l).

Calprotectin and lactoferrin levels in stool will compare to the clinical and laboratory parameters.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: September 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:All consecutive patients referred for endoscopic capsule -

Exclusion Criteria:Intake of nonsteroidal agents and/or antibiotics during the three months preceding the study, concomitant serious illness, pregnancy, alcohol abuse, and evidence of a respiratory tract infection.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Locations

Country	Name	City	State
Israel	Shaare Zedek	Jerusalem

Sponsors (1)

Lead Sponsor	Collaborator
Shaare Zedek Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	correlations between capsule and fecal markers	To assess the correlations between positive fecal markers and abnormal findings in endoscopic capsule	end of the study	No
Secondary	correlations between serum markers and capsule	correlations between CRP, ESR , PLT and abnormal findings in capsule	end of the study	No